| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus | 39 | 2025 | 771 | 7.590 |
Why?
|
| Potassium Channels, Inwardly Rectifying | 19 | 2024 | 124 | 4.510 |
Why?
|
| Diabetes Mellitus, Type 1 | 20 | 2025 | 594 | 2.830 |
Why?
|
| Sulfonylurea Compounds | 14 | 2024 | 69 | 2.790 |
Why?
|
| Genetic Testing | 10 | 2021 | 566 | 2.420 |
Why?
|
| Infant, Newborn, Diseases | 9 | 2025 | 116 | 2.310 |
Why?
|
| Insulin | 16 | 2025 | 1191 | 2.160 |
Why?
|
| Mutation | 30 | 2024 | 4374 | 1.660 |
Why?
|
| Infant, Newborn | 31 | 2024 | 2611 | 1.650 |
Why?
|
| Hypoglycemic Agents | 11 | 2020 | 376 | 1.490 |
Why?
|
| Precision Medicine | 6 | 2023 | 456 | 1.360 |
Why?
|
| Pancreas | 7 | 2025 | 263 | 1.170 |
Why?
|
| Infant | 19 | 2024 | 3359 | 1.030 |
Why?
|
| Chromosomes, Human, Pair 6 | 3 | 2024 | 128 | 1.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 9 | 2025 | 1230 | 0.980 |
Why?
|
| Hyperglycemia | 5 | 2019 | 181 | 0.910 |
Why?
|
| Registries | 7 | 2019 | 998 | 0.850 |
Why?
|
| Insulin-Secreting Cells | 5 | 2020 | 442 | 0.690 |
Why?
|
| Humans | 73 | 2025 | 95992 | 0.680 |
Why?
|
| Internet | 2 | 2015 | 340 | 0.670 |
Why?
|
| Forkhead Transcription Factors | 3 | 2017 | 175 | 0.660 |
Why?
|
| Glyburide | 5 | 2024 | 31 | 0.640 |
Why?
|
| Genetic Diseases, X-Linked | 2 | 2017 | 37 | 0.630 |
Why?
|
| Child, Preschool | 13 | 2024 | 3969 | 0.630 |
Why?
|
| Immune System Diseases | 2 | 2017 | 27 | 0.630 |
Why?
|
| Developmental Disabilities | 4 | 2016 | 208 | 0.610 |
Why?
|
| Hypoglycemia | 2 | 2017 | 112 | 0.600 |
Why?
|
| Diarrhea | 2 | 2017 | 180 | 0.590 |
Why?
|
| GATA6 Transcription Factor | 2 | 2020 | 13 | 0.590 |
Why?
|
| Child | 18 | 2025 | 7621 | 0.590 |
Why?
|
| Hyperinsulinism | 2 | 2019 | 48 | 0.560 |
Why?
|
| Hepatocyte Nuclear Factor 1-alpha | 2 | 2018 | 80 | 0.560 |
Why?
|
| Adolescent | 19 | 2025 | 9878 | 0.550 |
Why?
|
| Lamin Type A | 1 | 2018 | 26 | 0.540 |
Why?
|
| Sulfonylurea Receptors | 7 | 2024 | 50 | 0.540 |
Why?
|
| High-Throughput Nucleotide Sequencing | 4 | 2021 | 539 | 0.520 |
Why?
|
| Insulin Resistance | 2 | 2019 | 381 | 0.520 |
Why?
|
| Ovotesticular Disorders of Sex Development | 1 | 2017 | 4 | 0.520 |
Why?
|
| Anti-Mullerian Hormone | 1 | 2017 | 11 | 0.510 |
Why?
|
| Male | 40 | 2025 | 45792 | 0.510 |
Why?
|
| Congenital Hyperinsulinism | 3 | 2024 | 15 | 0.510 |
Why?
|
| Glucokinase | 4 | 2019 | 61 | 0.490 |
Why?
|
| Abnormalities, Multiple | 2 | 2018 | 240 | 0.490 |
Why?
|
| Estradiol | 1 | 2017 | 255 | 0.480 |
Why?
|
| Receptor, Insulin | 1 | 2016 | 60 | 0.480 |
Why?
|
| Female | 41 | 2025 | 49980 | 0.470 |
Why?
|
| Homozygote | 1 | 2016 | 209 | 0.470 |
Why?
|
| Insulin, Regular, Human | 1 | 2015 | 6 | 0.460 |
Why?
|
| Testosterone | 1 | 2017 | 276 | 0.460 |
Why?
|
| Self-Help Groups | 1 | 2015 | 14 | 0.460 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2016 | 116 | 0.460 |
Why?
|
| Gene Deletion | 1 | 2016 | 358 | 0.460 |
Why?
|
| Exons | 1 | 2016 | 454 | 0.440 |
Why?
|
| Genetic Diseases, Inborn | 2 | 2012 | 100 | 0.430 |
Why?
|
| Introns | 1 | 2015 | 304 | 0.420 |
Why?
|
| Antigens, CD | 1 | 2016 | 479 | 0.420 |
Why?
|
| Frameshift Mutation | 1 | 2013 | 54 | 0.410 |
Why?
|
| Family | 1 | 2015 | 331 | 0.400 |
Why?
|
| Microcephaly | 1 | 2013 | 79 | 0.400 |
Why?
|
| Infant, Premature, Diseases | 1 | 2014 | 85 | 0.400 |
Why?
|
| Epilepsy, Generalized | 1 | 2013 | 43 | 0.390 |
Why?
|
| Receptors, Drug | 3 | 2011 | 52 | 0.390 |
Why?
|
| Point Mutation | 1 | 2013 | 247 | 0.380 |
Why?
|
| Neonatal Screening | 2 | 2018 | 67 | 0.380 |
Why?
|
| ATP-Binding Cassette Transporters | 3 | 2011 | 142 | 0.370 |
Why?
|
| Blood Glucose | 4 | 2020 | 873 | 0.370 |
Why?
|
| Organoids | 2 | 2024 | 78 | 0.370 |
Why?
|
| DNA-Binding Proteins | 2 | 2018 | 1267 | 0.360 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2020 | 2474 | 0.350 |
Why?
|
| Genetic Variation | 1 | 2018 | 1424 | 0.340 |
Why?
|
| Insulin Infusion Systems | 2 | 2021 | 44 | 0.320 |
Why?
|
| Pancreas, Artificial | 2 | 2021 | 32 | 0.320 |
Why?
|
| Carrier Proteins | 1 | 2013 | 682 | 0.320 |
Why?
|
| Regulatory Factor X Transcription Factors | 2 | 2024 | 11 | 0.320 |
Why?
|
| Fatal Outcome | 3 | 2016 | 303 | 0.310 |
Why?
|
| Genomics | 2 | 2013 | 857 | 0.310 |
Why?
|
| Transcription Factors | 2 | 2018 | 1729 | 0.300 |
Why?
|
| Adult | 21 | 2025 | 28636 | 0.290 |
Why?
|
| B-Lymphocytes | 6 | 2005 | 760 | 0.290 |
Why?
|
| Homeodomain Proteins | 2 | 2024 | 563 | 0.270 |
Why?
|
| Membrane Proteins | 1 | 2013 | 1275 | 0.250 |
Why?
|
| Islets of Langerhans | 4 | 2005 | 559 | 0.250 |
Why?
|
| CD4-Positive T-Lymphocytes | 6 | 2003 | 487 | 0.250 |
Why?
|
| Autoantibodies | 4 | 2024 | 281 | 0.240 |
Why?
|
| Amino Acid Substitution | 3 | 2016 | 336 | 0.240 |
Why?
|
| Infant, Small for Gestational Age | 2 | 2016 | 37 | 0.230 |
Why?
|
| Neurologic Manifestations | 2 | 2016 | 11 | 0.230 |
Why?
|
| Induced Pluripotent Stem Cells | 3 | 2024 | 140 | 0.220 |
Why?
|
| DNA Methylation | 2 | 2024 | 702 | 0.220 |
Why?
|
| Diagnosis, Differential | 3 | 2018 | 1618 | 0.200 |
Why?
|
| Nuclear Proteins | 2 | 2018 | 750 | 0.200 |
Why?
|
| Diabetes, Gestational | 1 | 2024 | 49 | 0.200 |
Why?
|
| Consensus | 2 | 2022 | 372 | 0.200 |
Why?
|
| Maternal-Fetal Exchange | 2 | 2002 | 78 | 0.190 |
Why?
|
| Remission Induction | 1 | 2024 | 750 | 0.190 |
Why?
|
| Growth and Development | 1 | 2022 | 14 | 0.180 |
Why?
|
| Case-Control Studies | 2 | 2017 | 1962 | 0.180 |
Why?
|
| T-Lymphocytes | 4 | 2018 | 1309 | 0.180 |
Why?
|
| Trans-Activators | 1 | 2024 | 446 | 0.170 |
Why?
|
| Endocrinology | 2 | 2020 | 50 | 0.170 |
Why?
|
| Sequence Analysis, DNA | 2 | 2015 | 911 | 0.170 |
Why?
|
| Self-Management | 1 | 2021 | 44 | 0.170 |
Why?
|
| Mutation, Missense | 2 | 2016 | 302 | 0.170 |
Why?
|
| Age of Onset | 2 | 2018 | 345 | 0.160 |
Why?
|
| DNA Copy Number Variations | 1 | 2021 | 192 | 0.160 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2024 | 677 | 0.160 |
Why?
|
| Intestinal Atresia | 2 | 2024 | 6 | 0.160 |
Why?
|
| United States | 8 | 2021 | 7785 | 0.150 |
Why?
|
| Heterozygote | 3 | 2023 | 383 | 0.150 |
Why?
|
| Psychomotor Performance | 2 | 2013 | 505 | 0.150 |
Why?
|
| Cost-Benefit Analysis | 2 | 2013 | 500 | 0.150 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2021 | 307 | 0.150 |
Why?
|
| Prognosis | 2 | 2018 | 3993 | 0.150 |
Why?
|
| Siblings | 2 | 2016 | 109 | 0.150 |
Why?
|
| Lymphocyte Activation | 6 | 2003 | 809 | 0.150 |
Why?
|
| Down Syndrome | 1 | 2019 | 53 | 0.150 |
Why?
|
| Young Adult | 8 | 2025 | 7034 | 0.150 |
Why?
|
| Severity of Illness Index | 2 | 2016 | 1982 | 0.150 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2025 | 3642 | 0.140 |
Why?
|
| Pregnancy in Diabetics | 1 | 2018 | 41 | 0.140 |
Why?
|
| Genomic Imprinting | 1 | 2018 | 32 | 0.140 |
Why?
|
| Histone Demethylases | 1 | 2018 | 34 | 0.140 |
Why?
|
| Vestibular Diseases | 1 | 2018 | 29 | 0.140 |
Why?
|
| Hematologic Diseases | 1 | 2018 | 78 | 0.140 |
Why?
|
| Cellular Reprogramming | 1 | 2018 | 51 | 0.140 |
Why?
|
| Patient Participation | 1 | 2020 | 241 | 0.140 |
Why?
|
| Gene Editing | 1 | 2018 | 52 | 0.140 |
Why?
|
| Lymph Nodes | 1 | 2001 | 554 | 0.140 |
Why?
|
| Infant, Extremely Premature | 1 | 2017 | 43 | 0.130 |
Why?
|
| Face | 1 | 2018 | 114 | 0.130 |
Why?
|
| Europe | 1 | 2018 | 351 | 0.130 |
Why?
|
| Genetic Markers | 1 | 2018 | 477 | 0.130 |
Why?
|
| Diagnostic Errors | 1 | 2018 | 161 | 0.130 |
Why?
|
| Chromosomes, Human, Y | 1 | 2017 | 26 | 0.130 |
Why?
|
| Prevalence | 2 | 2018 | 1355 | 0.130 |
Why?
|
| Pregnancy Outcome | 1 | 2018 | 273 | 0.130 |
Why?
|
| Mosaicism | 1 | 2017 | 74 | 0.130 |
Why?
|
| Epilepsy | 2 | 2012 | 452 | 0.130 |
Why?
|
| Bone Marrow Transplantation | 2 | 2016 | 291 | 0.120 |
Why?
|
| Autopsy | 1 | 2017 | 127 | 0.120 |
Why?
|
| Testis | 1 | 2017 | 152 | 0.120 |
Why?
|
| Acanthosis Nigricans | 1 | 2016 | 3 | 0.120 |
Why?
|
| Drug Resistance | 1 | 2017 | 235 | 0.120 |
Why?
|
| Mice, Inbred NOD | 5 | 2005 | 215 | 0.120 |
Why?
|
| Cohort Studies | 3 | 2018 | 3115 | 0.120 |
Why?
|
| Pedigree | 3 | 2023 | 978 | 0.120 |
Why?
|
| Goals | 2 | 2007 | 68 | 0.120 |
Why?
|
| Infant, Premature | 1 | 2017 | 308 | 0.120 |
Why?
|
| Ovary | 1 | 2017 | 267 | 0.120 |
Why?
|
| Gestational Age | 1 | 2016 | 343 | 0.110 |
Why?
|
| Recombinant Proteins | 2 | 2016 | 1006 | 0.110 |
Why?
|
| Models, Theoretical | 2 | 2019 | 504 | 0.110 |
Why?
|
| Retrospective Studies | 4 | 2018 | 10307 | 0.110 |
Why?
|
| Endocrine System Diseases | 1 | 2015 | 25 | 0.110 |
Why?
|
| Turner Syndrome | 1 | 2015 | 27 | 0.110 |
Why?
|
| Sleep Wake Disorders | 1 | 2016 | 128 | 0.110 |
Why?
|
| Hormone Replacement Therapy | 1 | 2016 | 97 | 0.110 |
Why?
|
| Neoplasm Proteins | 1 | 2018 | 547 | 0.110 |
Why?
|
| Community Networks | 1 | 2015 | 32 | 0.110 |
Why?
|
| Evidence-Based Practice | 1 | 2015 | 51 | 0.110 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2016 | 188 | 0.110 |
Why?
|
| Diazoxide | 1 | 2014 | 19 | 0.110 |
Why?
|
| Neuropsychological Tests | 1 | 2016 | 548 | 0.100 |
Why?
|
| Intensive Care, Neonatal | 1 | 2014 | 15 | 0.100 |
Why?
|
| Biomarkers | 2 | 2020 | 1931 | 0.100 |
Why?
|
| Blindness, Cortical | 1 | 2013 | 8 | 0.100 |
Why?
|
| Pediatrics | 1 | 2018 | 399 | 0.100 |
Why?
|
| Duodenal Obstruction | 1 | 2013 | 4 | 0.100 |
Why?
|
| Digestive System Abnormalities | 1 | 2013 | 13 | 0.100 |
Why?
|
| Gallbladder | 1 | 2013 | 33 | 0.100 |
Why?
|
| Intestinal Volvulus | 1 | 2013 | 10 | 0.100 |
Why?
|
| Organ Size | 2 | 2025 | 376 | 0.100 |
Why?
|
| Chicago | 3 | 2016 | 1505 | 0.100 |
Why?
|
| Genome, Human | 1 | 2018 | 823 | 0.100 |
Why?
|
| Pancreatic Diseases | 1 | 2013 | 59 | 0.100 |
Why?
|
| Congenital Abnormalities | 1 | 2013 | 67 | 0.100 |
Why?
|
| Animals | 17 | 2024 | 28901 | 0.100 |
Why?
|
| Career Choice | 2 | 2005 | 164 | 0.100 |
Why?
|
| Syndrome | 2 | 2013 | 450 | 0.100 |
Why?
|
| Uniparental Disomy | 1 | 2012 | 5 | 0.100 |
Why?
|
| Psychomotor Disorders | 1 | 2012 | 20 | 0.090 |
Why?
|
| Premature Birth | 1 | 2014 | 130 | 0.090 |
Why?
|
| DNA Mutational Analysis | 1 | 2013 | 548 | 0.090 |
Why?
|
| Middle Aged | 7 | 2025 | 28299 | 0.090 |
Why?
|
| Treatment Outcome | 4 | 2020 | 9228 | 0.090 |
Why?
|
| Nervous System Diseases | 1 | 2013 | 172 | 0.090 |
Why?
|
| Epidemiologic Research Design | 1 | 2011 | 23 | 0.090 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 3922 | 0.090 |
Why?
|
| Time Factors | 2 | 2019 | 5593 | 0.090 |
Why?
|
| Mice | 13 | 2018 | 12525 | 0.080 |
Why?
|
| Pregnancy | 4 | 2024 | 3239 | 0.080 |
Why?
|
| Brain | 1 | 2021 | 2479 | 0.080 |
Why?
|
| HLA-DQ Antigens | 1 | 2011 | 52 | 0.080 |
Why?
|
| Longitudinal Studies | 2 | 2011 | 1176 | 0.080 |
Why?
|
| Autoimmunity | 2 | 2018 | 191 | 0.080 |
Why?
|
| Quality Improvement | 1 | 2015 | 502 | 0.080 |
Why?
|
| Autoimmune Diseases | 2 | 2003 | 257 | 0.080 |
Why?
|
| Blood Glucose Self-Monitoring | 2 | 2021 | 62 | 0.080 |
Why?
|
| KATP Channels | 1 | 2010 | 20 | 0.080 |
Why?
|
| eIF-2 Kinase | 1 | 2010 | 50 | 0.080 |
Why?
|
| Quality of Life | 1 | 2018 | 1816 | 0.080 |
Why?
|
| Tooth Discoloration | 1 | 2009 | 2 | 0.080 |
Why?
|
| Students, Medical | 2 | 2005 | 455 | 0.070 |
Why?
|
| Lymphocyte Transfusion | 2 | 1999 | 40 | 0.070 |
Why?
|
| Minor Histocompatibility Antigens | 2 | 1999 | 40 | 0.070 |
Why?
|
| Isoantigens | 5 | 1999 | 72 | 0.070 |
Why?
|
| Attitude of Health Personnel | 2 | 2020 | 683 | 0.070 |
Why?
|
| Genetic Therapy | 1 | 2010 | 382 | 0.070 |
Why?
|
| Education, Graduate | 1 | 2007 | 13 | 0.070 |
Why?
|
| Diabetes Complications | 1 | 2008 | 175 | 0.060 |
Why?
|
| Algorithms | 2 | 2015 | 2018 | 0.060 |
Why?
|
| Lymphocytes | 2 | 1999 | 465 | 0.060 |
Why?
|
| Incidence | 1 | 2011 | 1723 | 0.060 |
Why?
|
| Attitude | 1 | 2007 | 137 | 0.060 |
Why?
|
| Research | 2 | 2005 | 265 | 0.060 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2018 | 429 | 0.060 |
Why?
|
| Histocompatibility Antigens Class II | 3 | 2005 | 173 | 0.060 |
Why?
|
| Consumer Behavior | 1 | 2005 | 32 | 0.060 |
Why?
|
| Mice, SCID | 2 | 2002 | 279 | 0.050 |
Why?
|
| Education, Medical | 1 | 2007 | 252 | 0.050 |
Why?
|
| Mice, Mutant Strains | 2 | 2001 | 232 | 0.050 |
Why?
|
| Mice, Transgenic | 3 | 2003 | 1642 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2024 | 4690 | 0.050 |
Why?
|
| Chemokines, CC | 1 | 2003 | 37 | 0.050 |
Why?
|
| Duodenum | 1 | 2024 | 112 | 0.050 |
Why?
|
| Phenotype | 3 | 2016 | 2575 | 0.050 |
Why?
|
| Myocarditis | 1 | 2003 | 62 | 0.050 |
Why?
|
| Adenosine Triphosphate | 1 | 2024 | 329 | 0.050 |
Why?
|
| Th1 Cells | 1 | 2003 | 171 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 8 | 2005 | 3483 | 0.050 |
Why?
|
| Orthopedics | 1 | 2004 | 138 | 0.050 |
Why?
|
| Biomedical Research | 1 | 2007 | 442 | 0.050 |
Why?
|
| Body Patterning | 1 | 2024 | 217 | 0.050 |
Why?
|
| Mice, Inbred DBA | 1 | 2002 | 149 | 0.050 |
Why?
|
| Agammaglobulinemia | 1 | 2002 | 20 | 0.050 |
Why?
|
| Antigen Presentation | 2 | 2003 | 229 | 0.040 |
Why?
|
| Birth Weight | 2 | 2018 | 152 | 0.040 |
Why?
|
| Cell Communication | 1 | 2003 | 220 | 0.040 |
Why?
|
| Mice, Inbred C3H | 5 | 1999 | 372 | 0.040 |
Why?
|
| Immunoglobulins | 1 | 2002 | 144 | 0.040 |
Why?
|
| Glutamate Decarboxylase | 2 | 2011 | 34 | 0.040 |
Why?
|
| Intestines | 1 | 2024 | 432 | 0.040 |
Why?
|
| Electrophysiology | 1 | 2021 | 408 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2001 | 292 | 0.040 |
Why?
|
| Expert Testimony | 1 | 2020 | 34 | 0.040 |
Why?
|
| Healthy Volunteers | 1 | 2021 | 157 | 0.040 |
Why?
|
| Microscopy, Confocal | 1 | 2021 | 286 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2023 | 458 | 0.040 |
Why?
|
| Cell Culture Techniques | 1 | 2021 | 197 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2021 | 211 | 0.040 |
Why?
|
| Patch-Clamp Techniques | 1 | 2021 | 402 | 0.040 |
Why?
|
| Computer Literacy | 1 | 2020 | 3 | 0.040 |
Why?
|
| Attitude to Computers | 1 | 2020 | 12 | 0.040 |
Why?
|
| Spleen | 1 | 2001 | 419 | 0.040 |
Why?
|
| United States Food and Drug Administration | 1 | 2021 | 147 | 0.040 |
Why?
|
| Monitoring, Ambulatory | 1 | 2020 | 33 | 0.040 |
Why?
|
| Gain of Function Mutation | 1 | 2020 | 15 | 0.040 |
Why?
|
| Cells, Cultured | 3 | 2018 | 2928 | 0.040 |
Why?
|
| In Vitro Techniques | 1 | 2021 | 1014 | 0.040 |
Why?
|
| Nitrogen | 1 | 1980 | 79 | 0.040 |
Why?
|
| Fetal Growth Retardation | 1 | 1980 | 72 | 0.040 |
Why?
|
| Diffusion of Innovation | 1 | 2020 | 79 | 0.040 |
Why?
|
| Congresses as Topic | 1 | 2020 | 125 | 0.040 |
Why?
|
| Organogenesis | 1 | 2020 | 51 | 0.040 |
Why?
|
| Zinc | 1 | 1980 | 101 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 5 | 1999 | 1124 | 0.040 |
Why?
|
| Neural Pathways | 1 | 2021 | 333 | 0.040 |
Why?
|
| Loss of Function Mutation | 1 | 2020 | 50 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2020 | 295 | 0.040 |
Why?
|
| CD4 Lymphocyte Count | 1 | 1999 | 74 | 0.040 |
Why?
|
| Histocompatibility Antigens | 1 | 1999 | 37 | 0.040 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2021 | 298 | 0.040 |
Why?
|
| Diagnostic Techniques, Endocrine | 1 | 2018 | 7 | 0.040 |
Why?
|
| CD28 Antigens | 1 | 1999 | 94 | 0.040 |
Why?
|
| Phantoms, Imaging | 1 | 2021 | 490 | 0.040 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2018 | 38 | 0.040 |
Why?
|
| Fibroblasts | 1 | 2021 | 776 | 0.040 |
Why?
|
| Patient-Centered Care | 1 | 2020 | 229 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2020 | 301 | 0.030 |
Why?
|
| Pathology, Molecular | 1 | 2018 | 34 | 0.030 |
Why?
|
| International Cooperation | 1 | 2018 | 134 | 0.030 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2018 | 74 | 0.030 |
Why?
|
| Abortion, Spontaneous | 1 | 2018 | 74 | 0.030 |
Why?
|
| CRISPR-Cas Systems | 1 | 2018 | 98 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2018 | 411 | 0.030 |
Why?
|
| Nerve Net | 1 | 2021 | 407 | 0.030 |
Why?
|
| Protein Engineering | 1 | 2018 | 150 | 0.030 |
Why?
|
| Intellectual Disability | 1 | 2018 | 203 | 0.030 |
Why?
|
| Hematopoietic Stem Cells | 1 | 1999 | 325 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2020 | 514 | 0.030 |
Why?
|
| Legal Guardians | 1 | 2016 | 7 | 0.030 |
Why?
|
| Immune Tolerance | 1 | 1999 | 385 | 0.030 |
Why?
|
| Selection Bias | 1 | 2016 | 38 | 0.030 |
Why?
|
| Hospitals, University | 1 | 2016 | 199 | 0.030 |
Why?
|
| Cell Division | 3 | 2005 | 701 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2020 | 570 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2020 | 1819 | 0.030 |
Why?
|
| Succinimides | 3 | 1999 | 12 | 0.030 |
Why?
|
| Fluoresceins | 3 | 1999 | 43 | 0.030 |
Why?
|
| Lymphocyte Culture Test, Mixed | 3 | 1999 | 73 | 0.030 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2015 | 48 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 2885 | 0.030 |
Why?
|
| Risk | 1 | 2016 | 666 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2021 | 1319 | 0.030 |
Why?
|
| Rare Diseases | 1 | 2015 | 71 | 0.030 |
Why?
|
| Self Report | 1 | 2016 | 329 | 0.030 |
Why?
|
| Consanguinity | 1 | 2014 | 73 | 0.030 |
Why?
|
| Patient Selection | 1 | 2018 | 708 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2018 | 645 | 0.030 |
Why?
|
| Hepatocyte Nuclear Factor 4 | 1 | 2013 | 30 | 0.030 |
Why?
|
| Parents | 1 | 2016 | 307 | 0.020 |
Why?
|
| Aged | 1 | 2011 | 20927 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2020 | 1662 | 0.020 |
Why?
|
| Fluorescent Dyes | 3 | 1999 | 262 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2024 | 3581 | 0.020 |
Why?
|
| Risk Factors | 1 | 2024 | 5992 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 1880 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2018 | 647 | 0.020 |
Why?
|
| Chromosome Duplication | 1 | 2012 | 8 | 0.020 |
Why?
|
| Remission, Spontaneous | 1 | 2012 | 45 | 0.020 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2013 | 157 | 0.020 |
Why?
|
| Eye Movements | 1 | 2013 | 119 | 0.020 |
Why?
|
| Antigen-Presenting Cells | 2 | 2005 | 145 | 0.020 |
Why?
|
| Chromosome Deletion | 1 | 2012 | 223 | 0.020 |
Why?
|
| Hand | 1 | 2013 | 167 | 0.020 |
Why?
|
| Fathers | 1 | 2012 | 82 | 0.020 |
Why?
|
| HLA-DQ alpha-Chains | 1 | 2011 | 17 | 0.020 |
Why?
|
| Research Design | 1 | 2015 | 630 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 1966 | 0.020 |
Why?
|
| C-Peptide | 1 | 2011 | 186 | 0.020 |
Why?
|
| Age Factors | 1 | 2015 | 1959 | 0.020 |
Why?
|
| Dental Enamel Hypoplasia | 1 | 2009 | 2 | 0.020 |
Why?
|
| Haplotypes | 1 | 2011 | 652 | 0.020 |
Why?
|
| Epitopes, T-Lymphocyte | 2 | 1999 | 96 | 0.020 |
Why?
|
| Adoptive Transfer | 2 | 1999 | 175 | 0.020 |
Why?
|
| Surveys and Questionnaires | 2 | 2007 | 2860 | 0.020 |
Why?
|
| Proinsulin | 1 | 2007 | 124 | 0.020 |
Why?
|
| Protein Precursors | 1 | 2007 | 138 | 0.020 |
Why?
|
| Genetic Linkage | 1 | 2007 | 620 | 0.010 |
Why?
|
| Chimera | 1 | 2005 | 53 | 0.010 |
Why?
|
| Protein Folding | 1 | 2007 | 295 | 0.010 |
Why?
|
| Potassium Channels | 1 | 2007 | 359 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 2005 | 297 | 0.010 |
Why?
|
| Antigens, Differentiation | 1 | 2005 | 139 | 0.010 |
Why?
|
| Pennsylvania | 1 | 2005 | 103 | 0.010 |
Why?
|
| Job Satisfaction | 1 | 2005 | 86 | 0.010 |
Why?
|
| Obesity | 1 | 2011 | 1029 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2007 | 2090 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2004 | 365 | 0.010 |
Why?
|
| Chemotaxis | 1 | 2003 | 74 | 0.010 |
Why?
|
| Interleukin-4 | 1 | 2003 | 135 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2007 | 3040 | 0.010 |
Why?
|
| Th2 Cells | 1 | 2003 | 151 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2003 | 462 | 0.010 |
Why?
|
| Education, Medical, Graduate | 1 | 2005 | 438 | 0.010 |
Why?
|
| Models, Biological | 1 | 2007 | 1810 | 0.010 |
Why?
|
| Myocardium | 1 | 2003 | 606 | 0.010 |
Why?
|
| Radiation Chimera | 1 | 1999 | 23 | 0.010 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2003 | 667 | 0.010 |
Why?
|
| Lymphopenia | 1 | 1999 | 31 | 0.010 |
Why?
|
| Crosses, Genetic | 1 | 1999 | 171 | 0.010 |
Why?
|
| Transplantation, Isogeneic | 1 | 1999 | 40 | 0.010 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 1999 | 47 | 0.010 |
Why?
|
| Transplantation Immunology | 1 | 1999 | 83 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 1999 | 226 | 0.010 |
Why?
|
| Feces | 1 | 1980 | 360 | 0.010 |
Why?
|
| Diet | 1 | 1980 | 460 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 1999 | 725 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 1999 | 1023 | 0.010 |
Why?
|
| Immunity, Innate | 1 | 1999 | 464 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2003 | 2059 | 0.010 |
Why?
|
| Rats | 1 | 1980 | 4155 | 0.010 |
Why?
|